Related Experiment Video
Updated: Jul 1, 2026
13:01
Anti-Nuclear Antibody Screening Using HEp-2 Cells
Published on: June 24, 2014
[Systemic ANCA-associated vasculitis--diagnosis and therapy]
Ute Eisenberger1, Christof Hess
1Klinik und Poliklinik für Nephrologie und Hypertonie, Universitätsspital Bern, Bern.
Therapeutische Umschau. Revue Therapeutique
|July 16, 2008
Summary
Anti-Neutrophil Cytoplasmatic Autoantibody (ANCA)-associated vasculitis involves small-vessel inflammation. Diagnosis relies on clinical evaluation, and treatment balances efficacy against long-term toxicity for chronic or relapsing conditions.
Area of Science:
- Rheumatology
- Immunology
- Pathology
Context:
- ANCA-associated vasculitis (AAV) encompasses conditions like Wegener's granulomatosis, microscopic polyangiitis, and Churg-Strauss syndrome.
- These pauci-immune small-vessel vasculitides are characterized by the presence of pathogenic Anti-Neutrophil Cytoplasmatic Autoantibodies (ANCA).
- While diagnostic tools have advanced, clinical presentation remains crucial for accurate diagnosis.
Purpose:
- To provide an overview of ANCA-associated vasculitis, including its classification, pathogenesis, diagnosis, and therapeutic considerations.
- To highlight the shift in clinical focus towards managing chronic disease and relapses in AAV.
- To emphasize the importance of balancing treatment efficacy with long-term toxicity.
Summary:
- AAV affects small arteries, venules, and capillaries, distinguished by a lack of immunocomplexes on immunohistology.
- Pathogenesis is linked to Anti-Neutrophil Cytoplasmatic Autoantibodies (ANCA).
- Recent therapeutic studies have improved treatment strategies, adapting them to individual patient needs and disease states.
Impact:
- Improved understanding of AAV pathogenesis and clinical manifestations.
- Enhanced diagnostic approaches integrating clinical assessment with technical tools.
- Development of more personalized and effective treatment regimens for AAV patients.
- Better management strategies for both acute and chronic/relapsing forms of AAV, considering long-term outcomes and toxicity.
More Related Videos
06:35An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
05:14Characterization of Vascular Morphology of Neovascular Age-Related Macular Degeneration by Indocyanine Green Angiography
Published on: August 11, 2023
Related Concept Videos
01:17Pericarditis III: Medical Management
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:21Aneurysm II: Clinical Manifestations and Diagnostic Studies
Thoracic, aortic arch and abdominal aneurysms are significant vascular conditions that can present with various clinical manifestations and lead to serious complications. Understanding these manifestations and the appropriate diagnostic studies is essential for effective management and treatment.Thoracic Aortic AneurysmsThoracic aortic aneurysms often remain asymptomatic until they reach a size that impinges on adjacent structures. They typically cause deep, diffuse chest pain that radiates to...
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
01:26Nephrotic Syndrome II : Assessment and Medical Management
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...